@everythingyouneedtoknow This is a very old quote from a panel on HRT regimens, but it's interesting. Note that Oestrogel was marketed by a different pharmaceutical company.
A RETROSPECTIVE ASSESSMENT OF SIXTEEN YEARS
EXPERIENCE WITH OESTROGEL® IN THREE SPECIALIST
MENOPAUSE CLINICS
NJ Colville, KE Morris, D Ross, VA Godfiee, AJ Cooper, CP
Soencer. MI Whitehead.
King’s College Hospital, London, SE5 9RS, Amarant Centre,
London, SE1 7PW, Queen Charlotte’s & Chelsea Hospital, London,
W6 OXG. UK.
Oestrogel® (Hoechst Marion Roussel, Denham, UK) is a 17beta-
oestradiol gel for cutaneous application. Widely used by
postmenopausal women in France, it has only recently been licensed
in the UK, but was previously used on a named-patient basis by
specialist centres. We report the results of a case records review of
these patients.
Analysis has so far been performed on 75 cases. The cohort has a
mean ± SD age of 57.4 f 8.8 years and a mean ± SD age at LMP or
onset of climacteric symptoms of 45.4 ± 7.1 years. Forty-three
(57%) had had a premenopausal hysterectomy (H), of whom 15
(20% of total) had also had a premenopausal BSO (H+BSO). Age at
menopause was lowest in the H+BSO group (41.7 ± 8.8); age at
onset of climacteric symptoms was significantly lower in
hysterectomised, non-oophorectomised women than in women with
an intact uterus (44.3 ± 6.9 vs. 48.2 ± 5.3, p=O.O2), confirming
previous reports of the effect of hysterectomy.
Oestrogel® was the first HRT used by 24 women (34%). Among
those who had switched from other therapies, 41 (80%) had
previously used oral preparations, 36 (71%) transdermal patches and
13 (25%) implants. Reasons given for stopping these therapies
included poor symptom relief in 35 (69%), skin irritation or poor
patch adhesion in 19 (37%), other side effects in 15 (29%) and
implant tachyphylaxis in 10 (20%). At their last visit 59 women
(79%) were still using Oestrogel® the mean duration of use was 7.1
± 5.4 years. Women who stopped Oestrogel® had used it for a mean
of 5.9 ± 5.3 years. Reasons for stopping Oestrogel® were: poor
symptom relief (3) messy to use (3) side effects (3), switched to a
no-bleed treatment (3) and other (4). Mean ± SD plasma oestradiol
in women using 5 g/d Oestrogel® (3 mg/d 17beta-oestradiol) was 349 ±
204 pmol/l.